Imaging Tumor Burden in the Brain with 89Zr-Transferrin

摘要: The effective management of tumors in the brain imposes several unique clinical challenges. For example, complete surgical resection a primary tumor—a critical factor influencing prognosis—is often complicated by atypical tumor margins or proximity to essential neurologic tissue (1,2). Moreover, because blood–brain barrier can obstruct delivery systemically administered therapeutics, pharmacokinetic limitations drugs designed address metastatic severely dampen responses (3). With some success, noninvasive imaging modalities have been invoked these One most visible examples progress has use MR localize mass monitor burden after therapy (4). However, low sensitivity this modality, and its inability distinguish from nonmalignant pathologies (infection), precludes application common issues (e.g., detection residual recurrent subclinical disease). Because comparatively lower limit, ability intercalate biology independent morphologic changes, nuclear medicine technologies PET) are regarded as an attractive complement anatomic imaging. Indeed, studies conducted with (18F-FDG) investigational radiotracers (3′-deoxy-3′-18F-fluorothymidine, 11C-labeled amino acids), resulting degree disease contrast effectively establishing proof concept (5). shortcomings documented generally attributed obfuscating uptake normal tissue, ongoing questions concerning mechanism action, practical studying rapid decay kinetics. On basis observations, we hypothesized that 89Zr-transferrin, radiotracer previously developed target transferrin receptor (TFRC) prostate cancer (6), could be useful tool for monitoring brain. there is known tropism (7,8), leading groups exploit property therapeutically coupling anticancer foster tumor-specific (9–12). our previous work (and 89Zr-labeled monoclonal antibodies) resulted high-contrast images tumors, tissues (13,14). Part success 89Zr itself—the radionuclide highly physical properties such long half-life (~78 h), which well suited length time required large biomolecules distribute vivo (15). Collectively, observations led us profile avidity models 89Zr-transferrin.